Marco Tagliamento, MD, Gustave Roussy, Villejuif, France, presents a post-hoc patient-level pooled analysis of alectinib versus crizotinib from the Phase III ALEX (NCT02075840) and J-ALEX (JapicCTI-132316) trials in ALK-positive advanced non-small cell lung cancer (NSCLC) naïve to ALK inhibitors. The primary endpoint in both studies was progression-free survival (PFS). The analysis includes 500 patients, with alecensa showing significantly prolonged PFS over crizotinib. Multivariate analysis reveals that high tumor burden (hTB) is a prognostic factor for worse PFS regardless of treatment, while a body mass index (BMI) ≥25 is linked to better overall-survival (OS). Subgroup analysis indicates a significant interaction between treatment and TB. Adverse events were lower with alecensa. The findings suggest the importance of considering hTB and BMI in treatment decisions for advanced ALK+ NSCLC. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.